GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SkinBioTherapeutics SBTX.L · GBp

Consumer Staples · LSE · 🇬🇧 United Kingdom

Compare

4.75p

0.00%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in GBP, from our data supplier.

FY2025

Revenue

£4.6m

FY2016FY2025

Net income

−£696,253

FY2016FY2025

Free cash flow

−£1.3m

FY2016FY2025

Shareholders' equity

£9.4m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue£4.6m£1.2m£132,057£74,761—————£2,769
Gross profit£2.7m£683,038£85,190£45,337−£5,055−£5,100−£3,400——£2,769
Research and development£127,347£562,911£930,636£861,383£505,627£635,226£708,081£415,902£156,726£1,292
Operating income−£826,786−£2.9m−£3.0m−£3.0m−£1.5m−£1.6m−£1.4m−£941,000−£673,000−£4,201
Net income−£696,253−£2.9m−£2.8m−£2.8m−£1.4m−£1.5m−£1.1m−£844,000−£646,000−£4,201
Diluted earnings per share-0.00-0.01-0.02-0.02-0.01-0.01-0.01-0.01-0.01-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets£12.1m£5.2m£2.6m£3.1m£5.7m£2.8m£3.9m£3.7m£4.3m£423,488
Cash and short-term investments£4.8m£800,904£1.3m£1.8m£4.6m£2.2m£3.1m£3.2m£3.9m£256,667
Total liabilities£2.7m£2.2m£599,342£609,606£519,673£304,826£121,334£209,293£118,660£33,641
Debt£993,466£818,742£100,646£127,864£139,854—————
Shareholders' equity£9.4m£3.0m£2.0m£2.5m£5.2m£2.5m£3.8m£3.4m£4.2m£389,847
Shares outstanding259m223m177m157m157m133m122m119m119m119m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−£1.3m−£2.7m−£2.6m−£2.7m−£1.6m−£892,137−£1.4m−£667,745−£609,703−£1,167
Capital spending−£6,297−£198,169−£165,277−£96,813−£112,305−£73,668−£10,200−£72,260−£79,198−£136,214
Free cash flow−£1.3m−£2.9m−£2.8m−£2.8m−£1.7m−£965,805−£1.4m−£740,005−£688,901−£137,381

Latest quarters

By quarter end

Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Mar 2023Dec 2022Sept 2022
Revenue£3.1m£1.6m£1.1m£106,576£55,072£28,000£76,985£38,493
Gross profit£1.8m£877,564£574,284£68,223£5,609£17,000£35,388£25,869
Operating income−£87,586−£1.0m−£1.5m−£1.4m−£1.6m−£826,000−£1.4m−£675,545
Net income£337,847−£1.0m−£1.5m−£1.3m−£1.6m−£775,000−£1.3m−£642,502
Diluted earnings per share0.00-0.00-0.01-0.01-0.01-0.00-0.01-0.00
Cash from operations——−£1.0m−£1.0m−£1.0m———
Total assets£12.1m£7.3m£5.2m£4.2m£2.6m£2.6m£2.0m£2.0m
Cash and short-term investments£4.8m£1.2m£800,904£2.8m£1.3m£1.3m£765,976£765,976
Debt£824,224£1.1m£778,881£74,722£31,045£70,000£26,686—
Shareholders' equity£9.4m£4.5m£3.0m£3.7m£2.0m£2.0m£1.2m−£8.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue295.9%——
Operating income-34.8%-12.6%—
Net income-37.1%-14.2%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin58.0%58.1%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-28.4-7.0-4.6-4.2-22.3-10.1-7.5-9.2-8.1
Price to sales4.316.699.0157.6—————

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.